These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 7140182)

  • 1. [Beta-blockers and arterial hypertension: comparison between nadolol and propranolol].
    Abate G; Polimeni RM; Di Peppe MC; Guarino F; Troja C; Marisi F; Cerritelli E; Brillante C; De Angelis M
    Clin Ter; 1982 Aug; 102(3):283-291. PubMed ID: 7140182
    [No Abstract]   [Full Text] [Related]  

  • 2. [Nadolol, a long-term acting beta blocking agent, in the treatment of essential arterial hypertension].
    Semplicini A; Pessina AC; Rossi GP; Tagliafierro R; Lusiani L; Castellani V; Bedogni F; Mazzucato A; Ronsisvalle G
    Cardiologia; 1982 Sep; 27(9):853-64. PubMed ID: 6765278
    [No Abstract]   [Full Text] [Related]  

  • 3. Nadolol and propranolol in the treatment of hypertension: a double-blind comparison.
    El Mehairy MM; Shaker A; Ramadan M; Hamza S; Tadros SS
    J Int Med Res; 1980; 8(3):193-8. PubMed ID: 6104614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nadolol, a once daily treatment for hypertension: multi-centre clinical evaluation.
    Jackson DA
    Br J Clin Pract; 1980 Jul; 34(7):211-21. PubMed ID: 6107120
    [No Abstract]   [Full Text] [Related]  

  • 5. [The comparative results of a short course of nadolol and propranolol treatment of arterial hypertension patients (cooperative research). The Working Group of the Cooperative Program for the Study of New Preparations in Preventing Arterial Hypertension].
    Ter Arkh; 1989; 61(12):30-6. PubMed ID: 2697955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of essential arterial hypertension with nadolol and bendroflumethiazide].
    Marchetta F; Chiarini C; Degli Esposti E; Santoro A; Sturani A; Zuccalà A; Zucchelli P
    Clin Ter; 1983 Aug; 106(3):209-12. PubMed ID: 6627892
    [No Abstract]   [Full Text] [Related]  

  • 7. [Efficacy of the nadolol-bendroflumethiazide combination in the treatment of arterial hypertension].
    Zecchi P; Bellocci F; Santarelli P; Iannarelli M
    Clin Ter; 1986 Jan; 116(1):19-24. PubMed ID: 2870837
    [No Abstract]   [Full Text] [Related]  

  • 8. [Evaluation of the antihypertensive effect and tolerability of nadolol administered alone or in association with bendroflumethiazide].
    Gragnoli G; Righi GA; Turchetti V; Mondillo S; Kristodhullu A
    Minerva Med; 1984 Nov; 75(43):2609-15. PubMed ID: 6392936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of celiprolol and propranolol in the treatment of hypertension.
    Taylor S; Beattie A; Capone P
    Br J Clin Pract Suppl; 1985 Jun; 40():78-9. PubMed ID: 2864071
    [No Abstract]   [Full Text] [Related]  

  • 10. [Comparative study of the anti-angina effectiveness of nadolol and propranolol].
    Cremonesi A; Pagliarani PL; Guelfi P; Mattace R; Costa G; Bernardi G; Zacà F
    Boll Soc Ital Cardiol; 1979; 24(7):741-5. PubMed ID: 45306
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-acting beta-blockers in the twenty-fourth hour. A comparison in hypertension.
    Hackett GI; Harrison P; Kershaw S
    Practitioner; 1981 May; 225(1355):752-5. PubMed ID: 7027230
    [No Abstract]   [Full Text] [Related]  

  • 12. Beta-blockers and the kidney.
    Epstein M; Oster JR
    Miner Electrolyte Metab; 1982 Nov; 8(5):237-54. PubMed ID: 6132329
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of essential hypertension. A comparison between nadolol, once daily, and propranolol, four times daily.
    Frithz G
    Practitioner; 1982 Mar; 226(1365):562-4. PubMed ID: 7045847
    [No Abstract]   [Full Text] [Related]  

  • 14. A long-term evaluation of nadolol, a long-acting beta-adrenergic blocking agent, in the management of hypertension in general practice.
    O'Callaghan EG
    Br J Clin Pract; 1982 Jun; 36(6):235-9. PubMed ID: 6128994
    [No Abstract]   [Full Text] [Related]  

  • 15. Prolonged bradycardia after neostigmine administration in a patient taking nadolol.
    Seidl DC; Martin DE
    Anesth Analg; 1984 Mar; 63(3):365-7. PubMed ID: 6703355
    [No Abstract]   [Full Text] [Related]  

  • 16. [Nadolol, a long-acting beta-blocker, in the treatment of essential arterial hypertension].
    Semplicini A; Pessina AC; Rossi GP; Tagliafierro R; Lusiani L; Castellani V; Bedogni F; Mazzucato A; Ronsisvalle G
    Cardiologia; 1982 Sep; 27(9):853-64. PubMed ID: 6765448
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical, cardio- and hemodynamic effects of long- and short-acting beta-adrenergic blockers in the treatment of patients with stable stenocardia].
    Ol'binskaia LI; Bragina GI
    Kardiologiia; 1984 Apr; 24(4):9-13. PubMed ID: 6727119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical evaluation of the hypotensive effects of nadolol].
    Hanzlik J; Sodolski W; Stelmasiak T; Wolański I
    Kardiol Pol; 1982; 25(2):101-6. PubMed ID: 6125620
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison between short-term renal haemodynamic effects of propranolol and nadolol in essential hypertension: a cross-over study.
    Danesh BJ; Brunton J; Sumner DJ
    Clin Sci (Lond); 1984 Aug; 67(2):243-8. PubMed ID: 6146425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral hemodynamic effects of short-term nadolol administration in essential hypertension.
    Levenson J; Simon AC; Moyse D; Bouthier J; Safar ME
    Am Heart J; 1984 Oct; 108(4 Pt 2):1177-82. PubMed ID: 6148882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.